Effective targeting may potentially include targeting of specific dysfunctional cell states (such as SPP1+ TAMs, peripheral Tregs), disruption of pro-tumor communication pathways (such as SPP1-CD44, CD74-MIF), and should account for the spatial context of the TME, including MMR status which shapes these cellular interactions. The gene discussed is MRC1; the disease is neoplasm.